Search

everythinglearnresearchcommunity

for

Search:↓

Prostate cancer cells can make their own androgens to activate the androgen receptor, and treatments like abiraterone may increase this ability, suggesting new therapies should target the entire steroid-making pathway.

A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.

Genetic differences within ethnic groups may affect prostate cancer treatment effectiveness.

Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.

The ABI1 gene contributes to prostate cancer progression and treatment resistance.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.

Higher cholesterol levels increase aggressive prostate cancer risk.

In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

Finasteride for hair loss is safe and does not increase the risk of high-grade prostate cancer.

A new compound was effective for imaging prostate cancer in rats.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.

Fasting may reduce chemotherapy side effects.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.

Using a single PSA level to decide on a prostate biopsy is not effective; a more personalized approach considering various factors is recommended.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.

Finasteride treats hair loss but may affect prostate cancer detection.

Dutasteride and finasteride have similar effects on prostate cancer risk in BPH patients.

Finasteride for hair loss lowers PSA levels, so PSA values need adjusting when screening for prostate cancer.